Skip to main content
SpringerLink
Log in

Antiprogestin Pharmacodynamics, Pharmacokinetics, and Metabolism: Implications for Their Long-Term Use

  • Published:
Journal of Pharmacokinetics and Biopharmaceutics Aims and scope Submit manuscript

Abstract

Antiprogestins represent a relatively new and promising class of therapeutic agents that could have significant impact on human health and reproduction. In the present work, the pharmacodynamics, Pharmacokinetics, and metabolism of mifepristone (MIF), lilopristone (LIL), and onapristone (ONA) in humans are reviewed, and characteristics bearing important clinical implications are discussed. Although MIF has gained notoriety as an “abortion pill,” antiprogestins may more importantly prove effective in the treatment of endometriosis, uterine leiomyoma, meningioma, cancers of the breast and prostate, and as contraceptive agents. MIF pharmacokinetics display nonlinearities associated with saturable plasma protein (α 1 -acid glycoprotein, AAG) binding and characterized by lack of dose dependency for parent drug plasma concentrations (for doses greater than 100 mg) and a zero-order phase of elimination. LIL and ONA pharmacokinetics are less well characterized but ONA does not appear to bind AAG and displays a much shorter t1/2 than the other agents. The three antiprogestins are substrates of cytochrome P450 (CYP) 3A4, an enzyme exceedingly important in human xenobiotic metabolism. Even more implicative of likely drug–drug interactions subsequent to their long-term administration are recent data from our laboratory indicating that they inactivate CYP3A4 in a cofactor- and time-dependent manner, suggesting that complexation and induction of the enzyme may occur in vivo via protein stabilization. Moreover, it has been demonstrated that MIF increases CYP3A4 mRNA levels in human hepatocytes in primary culture, indicative of message stabilization and/or transcriplional activation of CYP3A4 expression. Finally, MIF has also been shown to inhibit P-glycoprotein function. Whether LIL and ONA share these latter two characteristics with MIF has not yet been determined but they illustrate properties that, in addition to diminished antiglucocorticoid activities and altered pharmacokinetic characteristics, warrant consideration during the development of these and newer antiprogestational agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. G. Pincus. The Control of Fertility, Academic Press, New York, 1965, pp. 128–138.

    Google Scholar 

  2. A. Ulmann, G. Teutsch, and D. Philibert. RU 486. Sci. Am. 262:42–48 (1990).

    CAS  PubMed  Google Scholar 

  3. C. P. Puri and P. F. A. Van Look. Newly developed competitive progesterone antagonists for fertility control. In M. K. Agarwal (ed.), Antihormones in Health and Disease: Proceedings of a Satellite Symposium of the 2nd European Congress of Endocrinology, Karger, Basel, 1991, pp. 127–167.

    Google Scholar 

  4. R. Wiechert and G. Neef. Synthesis of antiprogestational steroids. J. Steroid Biochem. 27:851–858 (1987).

    CAS  PubMed  Google Scholar 

  5. H. B. Croxatto, A. M. Salvatierra, B. Fuentealba, C. Zurth, and S. Beier. Effect of the antiprogestin onapristone on follicular growth in women. Hum. Reprod. 9:1442–1447 (1994).

    CAS  PubMed  Google Scholar 

  6. M. L. Swahn, L. Kovacs, S. Z. Cekan, A. R. Aedo, and P. Westlun. Termination of early pregnancy with ZK 98.734: pharmacokinetic behaviour and clinical effect. Hum. Reprod. 9:57–63 (1994).

    CAS  PubMed  Google Scholar 

  7. S. T. Cameron, H. O. Critchley, C. H. Buckley, T. Chard, R. W. Kelly, and D. T. Baird. The effects of post-ovulatory administration of onapristone on the development of a secretory endometrium. Hum. Reprod. 11:40–49 (1996).

    CAS  PubMed  Google Scholar 

  8. R. M. Evans. The steroid and thyroid hormone receptor superfamily. Science 240:889–895 (1988).

    CAS  PubMed  Google Scholar 

  9. M. Beato. Gene regulation by steroid hormones. Cell 56:335–344 (1989).

    CAS  PubMed  Google Scholar 

  10. B. W. O'Malley and M. J. Tsai. Molecular pathways of steroid receptor action. Biol. Reprod. 46:163–167 (1992).

    PubMed  Google Scholar 

  11. M. J. Tsai and B. W. O'Malley. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Ann. Rev. Biochem. 63:451–486 (1994).

    CAS  PubMed  Google Scholar 

  12. O. Heikinheimo, K. Kontula, H. Croxatto, I. Spitz, T. Luukkainen, and P. Lähteenmäki. Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. J. Steroid Biochem. 26:279–284 (1987).

    CAS  PubMed  Google Scholar 

  13. D. Philibert. RU 38486: An original multifaceted antihormone in vivo. In K. Agarwal (ed.), Adrenal Steroid Antagonism, Walter de Gruyter, Berlin, 1984, pp. 77–101.

    Google Scholar 

  14. G. F. Allan, X. Leng, S. Y. Tsai, N. L. Weigel, D. P. Edwards, M. J. Tsai, and B. W. O'Malley. Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J. Biol. Chem. 267:19513–19520 (1992).

    CAS  PubMed  Google Scholar 

  15. L. Klein-Hitpass, A. C. Cato, D. Henderson, and G. U. Ryffel. Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells. Nucleic Acids Res. 19:1227–1234 (1991).

    CAS  PubMed Central  PubMed  Google Scholar 

  16. G. Neef, S. Beier, W. Elger, D. Henderson, and R. Wiechert. New steroids with antiprogestational and antiglucocorticoid activities. Steroids 44:349–372 (1984).

    CAS  PubMed  Google Scholar 

  17. N. L. Weigel, C. A. Beck, P. A. Estes, P. Prendergast, M. Altmann, K. Christensen, and D. P. Edwards. Ligands induce conformational changes in the carboxyl-terminus of progesterone receptors which are detected by a site-directed antipeptide monoclonal antibody. Mol. Endocrinol. 6:1585–1597 (1992).

    CAS  PubMed  Google Scholar 

  18. E. Vegeto, G. F. Allan, W. T. Schrader, M. J. Tsai, D. P. McDonnell, and B. W. O'Malley. The mechanism of RU486 antagonism is dependent on the conformation of the carboxyterminal tail of the human progesterone receptor. Cell 90:703–713 (1992).

    Google Scholar 

  19. D. el Ashry, S. A. Onate, S. K. Nordeen, and D. P. Edwards. Human progesterone receptor complexed with the antagonist RU 486 binds to hormone response elements in a structurally altered form. Mol. Endocrinol. 3:1545–1558 (1989).

    CAS  PubMed  Google Scholar 

  20. M. E. Meyer, A. Pornon, J. W. Ji, M. T. Bocquel, P. Chambon, and H. Gronemeyer. Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor. EMBO J. 9:3923–3932 (1990).

    CAS  PubMed Central  PubMed  Google Scholar 

  21. D. P. Edwards, M. Altmann, A. DeMarzo, Y. Zhang, N. L. Weigel, and C. A. Beck. Progesterone receptor and the mechanism of action of progesterone antagonists. J. Steroid Biochem. Mol. Biol. 53:449–458 (1995).

    CAS  PubMed  Google Scholar 

  22. G. F. Allan, E. Lombardi, D. Haynes-Johnson, S. Palmer, M. Kiddoe, P. Kraft, C. Campen, P. Rybczynski, D. W. Combs, and A. Phillips. Induction of a novel conformation in the progesterone receptor by ZK98299 involves a defined region of the carboxyl-terminal tail. Mol. Endocrinol. 10:1206–1213 (1996).

    CAS  PubMed  Google Scholar 

  23. G. S. Takimoto, D. M. Tasset, A. C. Eppert, and K. B. Horwitz. Hormone-induced progesterone receptor phosphorylation consists of sequential DNA-independent and DNA-dependent stages: analysis with zinc finger mutants and the progesterone antagonist ZK98299. Proc. Natl. Acad. Sci. U.S. 89:3050–3054 (1992).

    CAS  Google Scholar 

  24. M. T. Bocquel, J. Ji, T. Ylikomi, B. Benhamou, A. Vergezac, P. Chambon, and H. Gronemeyer. Type II antagonists impair the DNA binding of steroid hormone receptors without affecting dimerization. J. Steroid Biochem. Mol. Biol. 45:205–215 (1993).

    CAS  PubMed  Google Scholar 

  25. C. A. Beck, Y. Zhang, N. L. Weigel, and D. P. Edwards. Two types of antiprogestins have distinct effects on site-specific phosphorylation of human progesterone receptor. J. Biol. Chem. 271:1209–1217 (1996).

    CAS  PubMed  Google Scholar 

  26. C. A. Beck, N. L. Weigel, M. L. Moyer, S. K. Nordeen, and D. P. Edwards. The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. Proc. Natl. Acad. Sci. U.S. 90:4441–4445 (1993).

    CAS  Google Scholar 

  27. K. Delabre, M. A. Guiochon, and E. Milgrom. In vivo evidence against the existence of antiprogestins disrupting receptor binding to DNA. Proc. Natl. Acad. Sci. U.S. 90:4421–4425 (1993).

    CAS  Google Scholar 

  28. P. Kastner, A. Krust, B. Turcotte, U. Stropp, L. Tora, H. Gronemeyer, and P. Chambon. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 9:1603–1614 (1990).

    CAS  PubMed Central  PubMed  Google Scholar 

  29. L. L. Wei, P. Hawkins, C. Baker, B. Norris, P. L. Sheridan, and P. G. Quinn. An aminoterminal truncated progesterone receptor isoform, PRc, enhances progestin-induced transcriptional activity. Mol. Endocrinol. 10:1379–1387 (1996).

    CAS  PubMed  Google Scholar 

  30. M. T. Bocquel, V. Kumar, C. Stricker, P. Chambon, and H. Gronemeyer. The contribution of the N-and C-terminal regions of steroid receptors to activation of transcription is both receptor and cell-specific. Nucleic Acids Res. 17:2581–2595 (1989).

    CAS  PubMed Central  PubMed  Google Scholar 

  31. C. A. Sartorius, L. Tung, G. S. Takimoto, and K. B. Horwitz. Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonist by cAMP. J. Biol. Chem. 268:9262–9266 (1993).

    CAS  PubMed  Google Scholar 

  32. C. A. Sartorius, S. D. Groshong, L. A. Miller, R. L. Powell, L. Tung, G. S. Takimoto, and K. B. Horwitz. New T47D breast cancer cell lines for the independent study of progesterone B-and A-receptors: Only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res. 54:3868–3877 (1994).

    CAS  PubMed  Google Scholar 

  33. T. A. Jackson, J. K. Richer, D. L. Bain, G. S. Takimoto, L. Tung, and K. B. Horwitz. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR and SMRT. Mol. Endocrinol. 11:693–705 (1997).

    CAS  PubMed  Google Scholar 

  34. A. Gravanis, G. Schaison, M. George, J. de Brux, P. G. Satyaswaroop, E. E. Baulieu, and P. Robel. Endometrial and pituitary responses to the steroidal antiprogestin RU 486 in postmenopausal women. J. Clin. Endocrinol. Metab. 60:156–163 (1985).

    CAS  PubMed  Google Scholar 

  35. S. K. Nordeen, B. J. Bona, and M. L. Moyer. Latent agonist activity of the steroid antagonist, RU486, is unmasked in cells treated with activators of protein kinase A. Mol. Endocrinol. 7:731–742 (1993).

    CAS  PubMed  Google Scholar 

  36. J. S. Mymryk and T. K. Archer. Influence of hormone antagonists on chromatin remodeling and transcription factor binding to the mouse mammary tumor virus promoter in vivo. Mol. Endocrinol. 9:1825–1834 (1995).

    CAS  PubMed  Google Scholar 

  37. D. P. McDonnell and M. E. Goldman. RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism. J. Biol. Chem. 269:11945–11949 (1994).

    CAS  PubMed  Google Scholar 

  38. N. Applezweig. Steroid Drugs, McGraw-Hill, New York, 1962, pp. 194–195.

    Google Scholar 

  39. E. E. Baulieu. RU 486—A decade on today and tomorrow. In M. Donaldson, L. Dorflinger, S. S. Brown, and L. Z. Benet (eds.), Clinical Applications of Mifepristone (RU 486) and Other Antiprogestins, National Academy Press, Washington, DC, 1993, pp. 71–119.

    Google Scholar 

  40. W. Herrmann, R. Wyss, A. Riondel, D. Philibert, G. Teutsch, E. Sakiz, and E. E. Baulieu. Effet d'un steroide anti-progesterone chez la femme: Interruption du cycle menstruel et de la grossesse au debut [The effects of an antiprogesterone steroid in women: Interruption of the menstrual cycle and of early pregnancy]. Compt. Rend. 294:933–938 (1982).

    CAS  Google Scholar 

  41. L. Kovacs, M. Sas, B. A. Resch, G. Ugocsai, M. L. Swahn, M. Bygdeman, and P. J. Rowe. Termination of very early pregnancy by RU 486—an antiprogestational compound. Contraception 29:399–410 (1984).

    CAS  PubMed  Google Scholar 

  42. B. Couzinet, S. N. Le, A. Ulmann, E. E. Baulieu, and G. Schaison. Termination of early pregnancy by the progesterone antagonist RU 486 (Mifepristone). New. Engl. J. Med. 315:1565–1570 (1986).

    CAS  PubMed  Google Scholar 

  43. D. J. Mishell, D. Shoupe, P. F. Brenner, M. Lacarra, J. Horenstein, P. Lähteenmäki, and I. M. Spitz. Termination of early gestation with the anti-progestin steroid RU 486: Medium vs. low dose. Contraception 35:307–321 (1987).

    CAS  PubMed  Google Scholar 

  44. D. A. Grimes, D. J. Mishell, D. Shoupe, and M. Lacarra. Early abortion with a single dose of the antiprogestin RU486. Am. J. Obstet. Gynecol. 158:1307–1312 (1988).

    CAS  PubMed  Google Scholar 

  45. M. Bygdeman and M. L. Swahn. Progesterone receptor blockage. Effect on uterine contractility and early pregnancy. Contraception 32:45–51 (1985).

    CAS  PubMed  Google Scholar 

  46. L. Cheng, R. W. Kelly, K. J. Thong, R. Hume, and D. T. Baird. The effect of mifepristone (RU486) on the immunohistochemical distribution of prostaglandin E and its metabolite in decidual and chorionic tissue in early pregnancy. J. Clin. Endocrinol. Metab. 77:873–877 (1993).

    CAS  PubMed  Google Scholar 

  47. L. Cheng, R. W. Kelly, K. J. Thong, R. Hume, and D. T. Baird. The effects of mifepristone (RU486) on prostaglandin dehydrogenase in decidual and chorionic tissue in early pregnancy. Hum. Reprod. 8:705–709 (1993).

    CAS  PubMed  Google Scholar 

  48. M. W. Rodger and D. T. Baird. Induction of therapeutic abortion in early pregnancy with mifepristone in combination with prostaglandin pessary. Lancet 2:1415–1418 (1987).

    CAS  PubMed  Google Scholar 

  49. M. L. Swahn and M. Bygdeman. Termination of early pregnancy with RU 486 (mifepristone) in combination with a prostaglandin analogue (sulprostone). Acta Obstet. Gynecol. Scand. 68:293–300 (1989).

    CAS  PubMed  Google Scholar 

  50. E. Aubeny and E. E. Baulieu. Activite contragestive de l'association an RU486 d'une prostaglandine active par voie orale [Contraceptive activity of RU486 and oral active prostaglandin combination]. Compt. Rend. 312:539–545 (1991).

    CAS  Google Scholar 

  51. N. C. Hill, J. Ferguson, and I. Z. MacKenzie. The efficacy of oral mifepristone (RU 38.486) with a prostaglandin E1 analog vaginal pessary for the termination of early pregnancy: Complications and patient acceptability. Am. J. Obstet. Gynecol. 162:414–417 (1990).

    CAS  PubMed  Google Scholar 

  52. The efficacy and tolerance of mifepristone and prostaglandin in first trimester termination of pregnancy. UK Multicentre Trial. Br. J. Obstet. Gynaecol. 97:480–486 (1990).

    Google Scholar 

  53. J. E. Norman, K. J. Thong, and D. T. Baird. Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone [see comments]. Lancet 338:1233–1236 (1991).

    CAS  PubMed  Google Scholar 

  54. R. Peyron, E. Aubeny, V. Targosz, L. Silvestre, M. Renault, F. Elkik, P. Leclerc, A. Ulmann, and E. E. Baulieu. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol [see comments]. New Engl. J. Med. 328:1509–1513 (1993).

    CAS  PubMed  Google Scholar 

  55. L. Silvestre, C. Dubois, M. Renault, Y. Rezvani, E. E. Baulieu, and A. Ulmann. Voluntary interruption of pregnancy with mifepristone (RU 486) and a prostaglandin analogue. A large-scale French experience [see comments]. New Engl. J. Med. 322:645–648 (1990).

    CAS  PubMed  Google Scholar 

  56. The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation; UK Multicentre Study—final results. Contraception 55:1–5 (1997).

  57. E. A. Schaff, L. S. Stadalius, S. H. Eisinger, and P. Franks. Vaginal misoprostol administered at home after mifepristone (RU486) for abortion. J. Fam. Practice 44:353–360 (1997).

    CAS  Google Scholar 

  58. D. Jannet, N. Afiak, A. Abankwa, B. Carbonne, L. Marpeau, and J. Milliez. Termination of 2nd and 3rd trimester pregnancies with mifepristone and misoprostol. Eur. J. Obstet. Gynecol. Reprod. Biol. 70:159–163 (1996).

    CAS  PubMed  Google Scholar 

  59. M. Donaldson, L. Dorflinger, S. S. Brown, and L. Z. Benet (eds.). Clinical Applications of Mifepristone (RU 486) and Other Antiprogestins, National Academy Press, Washington, DC, 1993.

    Google Scholar 

  60. M. L. Swahn, L. Kovacs, S. Z. Cekan, A. R. Aedo, and P. Westlund. Termination of early pregnancy with ZK 98.734; pharmacokinetic behavior and clinical effect. Hum. Reprod. 9:57–63 (1994).

    CAS  PubMed  Google Scholar 

  61. R. Wiechert and G. Neef. Synthesis of antiprogestational steroids. J. Steroid Biochem. 27:851–858 (1987).

    CAS  PubMed  Google Scholar 

  62. D. J. Gruol, M. C. Zee, J. Trotter, and S. Bourgeois. Reversal of multidrug resistance by RU 486. Cancer Res. 54:3088–3091 (1994).

    CAS  PubMed  Google Scholar 

  63. D. J. Gruol and S. Bourgeois. Expression of the mdrl P-glycoprotein gene: A mechanism of escape from glucocorticoid-induced apoptosis. Biochem. Cell Biol. 72:561–571 (1994).

    CAS  PubMed  Google Scholar 

  64. V. Lecureur, O. Fardel, and A. Guillouzo. The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. FEBS Lett. 355:187–191 (1994).

    CAS  PubMed  Google Scholar 

  65. O. Fardel, A. Courtois, B. Drenou, T. Lamy, V. Lecureur, P. Y. le Prise, and R. Fauchet. Inhibition of P-glycoprotein activity in human leukemic cells by mifepristone. Anticancer Drugs 7:671–677 (1996).

    CAS  PubMed  Google Scholar 

  66. L. M. Kettel, A. A. Murphy, A. J. Morales, and S. S. Yen. Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum. Reprod. 9(Suppl. 1):116–120 (1994).

    PubMed  Google Scholar 

  67. L. M. Kettel, A. A. Murphy, A. J. Morales, A. Ulmann, E. E. Baulieu, and S. S. Yen. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil. Steril. 65:23–28 (1996).

    CAS  PubMed  Google Scholar 

  68. V. J. Buttram and R. C. Reiter. Uterine leiomyomata: Etiology, symptomatology, and management. Fertil. Steril. 36:433–445 (1981).

    PubMed  Google Scholar 

  69. A. A. Murphy, L. M. Kettel, A. J. Morales, V. J. Roberts, and S. S. Yen. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J. Clin. Endocrinol. Metab. 76:513–517 (1993).

    CAS  PubMed  Google Scholar 

  70. R. S. Carroll, D. Glowacka, and K. Dashner. Progesterone receptor expression in meningiomas. Cancer Res. 53:1312–1316 (1993).

    CAS  PubMed  Google Scholar 

  71. Y. Matsuda, K. Kawamoto, K. Kiya, K. Kurisu, K. Sugiyama, and T. Uozumi. Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo. J. Neurosurg. 80:527–534 (1994).

    CAS  PubMed  Google Scholar 

  72. S. M. Grunberg. Role of antiprogestational therapy for meningiomas. Hum. Reprod. 9(Suppl. 1):202–207 (1994).

    PubMed  Google Scholar 

  73. S. Bardon, F. Vignon, D. Chalbos, and H. Rochefort. RU486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor. J. Clin. Endocrinol. Metab. 60:692–697 (1985).

    CAS  PubMed  Google Scholar 

  74. G. H. Bakker, H. B. Setyono, M. S. Henkelman, F. H. de Jong, S. W. Lamberts, P. van der Schoot, and J. G. Klijn. Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors. Cancer Treat. Rev. 71:1021–1027 (1987).

    CAS  Google Scholar 

  75. R. L. Sutherland, R. E. Hall, G. Y. Pang, E. A. Musgrove, and C. L. Clarke. Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. Cancer Res. 48:5084–5091 (1988).

    CAS  PubMed  Google Scholar 

  76. R. T. Bowden, J. R. Hissom, and M. R. Moore. Growth stimulation of T47D human breast cancer cells by the anti-progestin RU486. Endocrinology 124:2642–2644 (1989).

    CAS  PubMed  Google Scholar 

  77. G. H. Bakker, H. B. Setyono, H. Portengen, F. H. De Jong, J. A. Foekens, and J. G. Klijn. Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors. Endocrinology 125:1593–1598 (1989).

    CAS  PubMed  Google Scholar 

  78. G. H. Bakker, H. B. Setyono, H. Portengen, F. H. De Jong, J. A. Foekens, and J. G. Klijn. Treatment of breast cancer with different antiprogestins: Preclinical and clinical studies. J. Steroid Biochem. Mol. Biol. 37:789–794 (1990).

    CAS  PubMed  Google Scholar 

  79. H. Michna, M. R. Schneider, Y. Nishino, and M. F. el Etreby. Antitumor activity of the antiprogestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors: Mechanistic studies. Breast Cancer Res. Treat. 14:275–288 (1989).

    CAS  PubMed  Google Scholar 

  80. G. Romieu, T. Maudelonde, A. Ulmann, H. Pujol, J. Grenier, G. Cavalie, S. Khalaf, and H. Rochefort. The antiprogestin RU486 in advanced breast cancer: Preliminary clinical trial. Bull. Cancer (Paris) 74:455–461 (1987).

    CAS  PubMed  Google Scholar 

  81. J. G. Klijn, F. H. De Jong, G. H. Bakker, S. W. Lamberts, C. J. Rodenburg, and F. J. Alexieva. Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res. 49:2851–2856 (1989).

    CAS  PubMed  Google Scholar 

  82. D. Perrault, E. A. Eisenhauer, K. I. Pritchard, L. Panasci, B. Norris, T. Vandenberg, and B. Fisher. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: A National Cancer Institute of Canada Clinical Trials Group study. J. Clin. Oncol. 14:2709–2712 (1996).

    CAS  PubMed  Google Scholar 

  83. O. Sartor and W. D. Figg. Mifepristone: antineoplastic studies. Clin. Obstet. Gynecol. 39:498–505 (1996).

    CAS  PubMed  Google Scholar 

  84. M. F. Lin, M. H. Kawachi, M. R. Stallcup, S. M. Grunberg, and F. F. Lin. Growth inhibition of androgen-insensitive human prostate carcinoma cells by a 19-norsteroid derivative agent, mifepristone. Prostate 26:194–204 (1995).

    CAS  PubMed  Google Scholar 

  85. W. L. Ledger, V. M. Sweeting, H. Hillier, and D. T. Baird. Inhibition of ovulation by low-dose mifepristone (RU 486). Hum. Reprod. 7:945–950 (1992).

    CAS  PubMed  Google Scholar 

  86. H. B. Croxatto, A. M. Salvatierra, H. D. Croxatto, and B. Fuentealba. Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle. Hum. Reprod. 8:201–207 (1993).

    CAS  PubMed  Google Scholar 

  87. I. M. Spitz, H. B. Croxatto, A. M. Salvatierra, and O. Heikinheimo. Response to intermittent RU486 in women. Fertil. Steril. 59:971–975 (1993).

    CAS  PubMed  Google Scholar 

  88. K. Gemzell-Danielsson, P. Westlund, E. Johannisson, M. L. Swahn, M. Bygdeman, and M. Seppala. Effect of low weekly doses of mifepristone on ovarian function and endometrial development. Hum. Reprod. 11:256–264 (1996).

    CAS  PubMed  Google Scholar 

  89. K. Gemzell-Danielsson, M. L. Swahn, P. Svalander, and M. Bygdeman. Early luteal phase treatment with mifepristone (RU 486) for fertility regulation. Hum. Reprod. 8:870–873 (1993).

    CAS  PubMed  Google Scholar 

  90. P. Dockery, R. M. Ismail, T. C. Li, M. A. Warren, and I. D. Cooke. The effect of a single dose of mifepristone (RU486) on the fine structure of the human endometrium during the early luteal phase. Hum. Reprod. 12:1778–1784 (1997).

    CAS  PubMed  Google Scholar 

  91. S. T. Cameron, H. O. Critchley, C. H. Buckley, R. W. Kelly, and D. T. Baird. Effects of two antiprogestins (mifepristone and onapristone) on endometrial factors of potential importance for implantation. Fertil. Steril. 67:1046–1053 (1997).

    CAS  PubMed  Google Scholar 

  92. P. Lähteenmäki, T. Rapeli, M. Kääriäinen, H. Alfthan, and O. Ylikorkala. Late postcoital treatment against pregnancy with antiprogesterone RU 486. Fertil. Steril. 50:36–38 (1988).

    PubMed  Google Scholar 

  93. B. Couzinet, S. N. Le, L. Silvestre, and G. Schaison. Late luteal administration of the antiprogesterone RU486 in normal women: Effects on the menstrual cycle events and fertility control in a long-term study. Fertil. Steril. 54:1039–1044 (1990).

    CAS  PubMed  Google Scholar 

  94. A. Glasier, K. J. Thong, M. Dewar, M. Mackie, and D. T. Baird. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception [see comments]. New Engl. J. Med. 327:1041–1044 (1992).

    CAS  PubMed  Google Scholar 

  95. A. M. Webb, J. Russell, and M. Elstein. Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception. Br. Med. J. 305:927–931 (1992).

    CAS  Google Scholar 

  96. O. Heikinheimo and D. F. Archer. Mifepristone: A potential contraceptive. Clin. Obstet. Gynecol. 39:461–468 (1996).

    CAS  PubMed  Google Scholar 

  97. R. Deraedt, C. Bonnet, M. Busigny, P. Chatelet, C. Cousty, M. Mouren, D. Philibert, J. Pottier, and J. Salmon. Pharmacokinetics of RU 486. In E. E. Beaulieu and S. I. Segal (eds.), The Antiprogestin Steroid RU 486 and Human Fertility Control, Plenum Press, New York, 1985, pp. 103–122.

    Google Scholar 

  98. P. Lähteenmäki, O. Heikinheimo, H. Croxatto, I. Spitz, D. Shoupe, L. Birgerson, and T. Luukkainen. Pharmacokinetics and metabolism of RU 486. J. Steroid Biochem. 27:859–863 (1987).

    PubMed  Google Scholar 

  99. R. Kekkonen, O. Heikinheimo, E. Mandelin, and P. Lähteenmäki. Pharmacokinetics of mifepristone after low oral doses. Contraception 54:229–234 (1996).

    CAS  PubMed  Google Scholar 

  100. E. E. Baulieu. Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor. Science 245:1351–1357 (1989).

    CAS  PubMed  Google Scholar 

  101. B. Grimaldi, C. Hamberger, D. Tremblay, J. Barre, and J. P. Tillement. In vitro study of the binding of RU 486 and RU 42633 to human serum proteins. Prog. Clin. Biol. Res. 300:445–448 (1989).

    CAS  PubMed  Google Scholar 

  102. O. Heikinheimo. Antiprogesterone steroid RU486. Pharmacokinetics and receptor binding in humans. Acta Obstet. Gynecol. Scand. 69:357–358 (1990).

    CAS  PubMed  Google Scholar 

  103. K. Nagoshi, N. Hayashi, and K. Sekiba. Automated direct assay system for RU38486, an antiprogesterone-antiglucocorticoid agent, and its metabolites using high performance liquid chromatography. Acta Med. Okayama 45:81–87 (1991).

    CAS  PubMed  Google Scholar 

  104. Y. E. Shi, Z. H. Ye, C. H. He, G. Q. Zhang, J. Q. Xu, L. P. Van, and K. Fotherby. Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women. Contraception 48:133–149 (1993).

    CAS  PubMed  Google Scholar 

  105. O. Heikinheimo. Pharmacokinetics of the antiprogesterone RU 486 in women during multiple dose administration. J. Steroid Biochem. 32:21–25 (1989).

    CAS  PubMed  Google Scholar 

  106. O. Heikinheimo, S. Ranta, S. Grunberg, P. Lähteenmäki, and I. M. Spitz. Alterations in the pituitary-thyroid and pituitary-adrenal axes—consequences of long-term mifepristone treatment. Metabolism 46:292–296 (1997).

    CAS  PubMed  Google Scholar 

  107. O. Heikinheimo, O. Ylikorkala, U. Turpeinen, and P. Lähteenmäki. Pharmacokinetics of the antiprogesterone RU 486: No correlation to clinical performance of RU 486. Acta Endocrinol. 123:298–304 (1990).

    CAS  PubMed  Google Scholar 

  108. P. F. A. Van Look and H. Von Hertzen. Antiprogestins: Perspectives from a Global Research Program. In M. S. Donaldson, L. Dorflinger, S. S. Brown, and L. Z. Benet (eds.), Clinical Applications of Mifepristone (RU 486) and Other Antiprogestins, National Academy Press, Washington, DC, 1993, pp. 253–277.

    Google Scholar 

  109. G. R. Jang, S. A. Wrighton, and L. Z. Benet. Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes. Biochem. Pharmacol. 52:753–761 (1996).

    CAS  PubMed  Google Scholar 

  110. S. A. Wrighton, M. VandenBranden, and B. J. Ring. The human drug metabolizing cytochromes P450. J. Pharmacokin. Biopharm. 24:461–473 (1996).

    CAS  Google Scholar 

  111. G. R. Jang and L. Z. Benet. Cytochrome P450 3A4 mediated N-demethylation of the antiprogestins lilopristone and onapristone. Drug Metab. Dispos. 25:1119–1122 (1997).

    CAS  PubMed  Google Scholar 

  112. G. R. Jang and L. Z. Benet. Antiprogestin-mediated inactivation of cytochrome P450 3A4. Pharmacology, 56:150–157 (1998).

    CAS  PubMed  Google Scholar 

  113. T. A. Kocarek, E. G. Schuetz, S. C. Stom, R. A. Fisher, and P. S. Guzelian. Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug Metab. Dispos. 23:415–421 (1995).

    CAS  PubMed  Google Scholar 

  114. L. Z. Benet, D. L. Kroetz, and L. B. Sheiner. Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination. In J. G. Hardman, L. E. Limbird, P. B. Molinoff, R. W. Ruddon, and A. G. Goodman (eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, 1996, chap. 1, pp. 3–27.

    Google Scholar 

  115. F. P. Guengerich, M. V. Martin, P. H. Beaune, P. Kremers, T. Wolff, and D. J. Waxman. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261:5051–5060 (1986).

    CAS  PubMed  Google Scholar 

  116. T. Kronbach, V. Fischer, and U. A. Meyer. Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin. Pharmacol. Ther. 43:630–635 (1988).

    CAS  PubMed  Google Scholar 

  117. M. Sattler, F. P. Guengerich, C. H. Yun, U. Christians, and K. F. Sewing. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab. Dispos. 20:753–761 (1992).

    CAS  PubMed  Google Scholar 

  118. T. Kronbach, D. Mathys, M. Umeno, F. J. Gonzalez, and U. A. Meyer. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol. 36:89–96 (1989).

    CAS  PubMed  Google Scholar 

  119. S. Imaoka, K. Enomoto, Y. Oda, A. Asada, M. Fujimon, T. Shimada, S. Fujita, F. P. Guengerich, and Y. Funae. Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s. J. Pharmacol. Exp. Ther. 255:1385–1391 (1990).

    CAS  PubMed  Google Scholar 

  120. J. M. Trivier, C. Libersa, C. Belloc, and M. Lhermitte. Amiodarone N-deethylation in human liver microsomes: Involvement of cytochrome P450 3A enzymes (first report). Life Sci. 52:PL91–96 (1993).

    CAS  PubMed  Google Scholar 

  121. G. Fabre, B. Julian, A. B. Saint, H. Joyeux, and Y. Berger. Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab. Dispos. 21:978–985 (1993).

    CAS  PubMed  Google Scholar 

  122. F. P. Guengerich, E. D. Muller, and I. A. Blair. Oxidation of quinidine by human liver cytochrome P-450. Mol. Pharmacol. 30:287–295 (1986).

    CAS  PubMed  Google Scholar 

  123. J. W. Harris, A. Rahman, B. R. Kim, F. P. Guengerich, and J. M. Collins. Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 54:4026–4035 (1994).

    CAS  PubMed  Google Scholar 

  124. M. V. Relling, R. Evans, C. Dass, D. M. Desiderio, and J. Nemec. Human cytochrome P450 metabolism of teniposide and etoposide. J. Pharmacol. Exp. Ther. 261:491–496 (1992).

    CAS  PubMed  Google Scholar 

  125. P. X. Zhou, E. Seree, X. J. Zhou, M. Placidi, P. Maurel, Y. Barra, and R. Rahmani. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: Drug interactions. Cancer Res. 53:5121–5126 (1993).

    PubMed  Google Scholar 

  126. X. J. Zhou, P. X. Zhou, T. Gauthier, M. Placidi, P. Maurel, and R. Rahmani. Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. Biochem. Pharmacol. 45:853–861 (1993).

    CAS  PubMed  Google Scholar 

  127. G. R. Wilkinson. Cytochrome P4503A (CYP3A) metabolism: Prediction of in vivo activity in humans. J. Pharmacokin. Biopharm. 24:475–490 (1996).

    CAS  Google Scholar 

  128. E. G. Schuetz and P. S. Guzelian. Induction of cytochrome P-450 by glucocorticoids in rat liver. II. Evidence that glucocorticoids regulate induction of cytochrome P-450 by a nonclassical receptor mechanism. J. Biol. Chem. 259:2007–2012 (1984).

    CAS  PubMed  Google Scholar 

  129. L. C. Quattrochi, A. S. Mills, J. L. Barwick, C. B. Yockey, and P. S. Guzelian. A novel cis-acting element in a liver cytochrome P450 3A gene confers synergistic induction by glucocorticoids plus antiglucocorticoids. J. Biol. Chem. 270:28917–28923 (1995).

    CAS  PubMed  Google Scholar 

  130. J. D. Schuetz, E. G. Schuetz, J. V. Thottassery, P. S. Guzelian, S. Strom, and D. Sun. Identification of a novel dexamethasone responsive enhancer in the human CYP3A5 gene and its activation in human and rat liver cells. Mol. Pharmacol. 49:63–72 (1996).

    CAS  PubMed  Google Scholar 

  131. L. Z. Benet, C.-Y. Wu, M. F. Hebert, and V. J. Wacher. Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery. J. Controlled Release 39:139–143 (1996).

    CAS  Google Scholar 

  132. K. S. Lown, D. G. Bailey, R. J. Fontana, S. K. Janardan, C. H. Adair, L. A. Fortlage, M. B. Brown, W. Guo, and P. B. Watkins. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest. 99:2545–2553 (1997).

    CAS  PubMed Central  PubMed  Google Scholar 

  133. K. S. Lown, R. R. Mayo, A. B. Leichtman, H. L. Hsiao, D. K. Turgeon, P. Schmiedlin-Ren, M. B. Brown, W. Guo, S. J. Rossi, L. Z. Benet, and P. B. Watkins. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62:248–260 (1997).

    CAS  PubMed  Google Scholar 

  134. V. J. Wacher, C. Y. Wu, and L. Z. Benet. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinogen. 13:129–134 (1995).

    CAS  Google Scholar 

Download references

Author information

Author notes

  1. Graham R. Jang

    Present address: Department of Biopharmaceutical Sciences, University of California, 513 Parnassus Avenue, San Francisco, California, 94143-0446

Authors and Affiliations

  1. Department of Biopharmaceutical Sciences, University of California, 513 Parnassus Avenue, San Francisco, California, 94143-0446

    Leslie Z. Benet

Authors
  1. Graham R. Jang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leslie Z. Benet
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jang, G.R., Benet, L.Z. Antiprogestin Pharmacodynamics, Pharmacokinetics, and Metabolism: Implications for Their Long-Term Use. J Pharmacokinet Pharmacodyn 25, 647–672 (1997). https://doi.org/10.1023/A:1025725716343

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1025725716343

Search

Navigation